Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio Acquires China Rights to ReViral's RSV Therapy in $119 Million Deal

publication date: Mar 2, 2021

LianBio, a Shanghai-Princeton, NJ biopharma, acquired China rights to a novel clinical-stage respiratory syncytial virus (RSV) therapy being developed by ReViral of London. Lian will make a $14 million upfront payment and also pay up to $105 million in milestones, plus royalties. ReViral's sisunatovir is an oral fusion inhibitor being tested in two global Phase II trials: one in children and the other in adult stem-cell transplant patients. Last year, LianBio was founded by Perceptive Investors, a US life science investment firm, to bring assets from Perceptive's portfolio companies to China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital